Abstract
Surgery is the standard of care for primary resectable gastrointestinal stromal tumors (GISTs), but half of surgically treated patients relapse. Imatinib (IM) has been shown to prolong recurrence-free survival after complete surgery and is now approved as adjuvant therapy (400 mg/day) for high-risk GIST patients. IM is well tolerated, with mild to moderate side effects observed. Whether adjuvant IM prolongs overall survival is under evaluation in two ongoing clinical trials. J. Surg. Oncol. 2011; 104:896-900.
| Original language | English |
|---|---|
| Pages (from-to) | 896-900 |
| Number of pages | 5 |
| Journal | Journal of Surgical Oncology |
| Volume | 104 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Dec 2011 |
Keywords
- adjuvant therapy
- adverse events
- gastrointestinal stromal tumor
- GIST
- imatinib
- risk stratification
ASJC Scopus subject areas
- Surgery
- Oncology